Eton Pharmaceuticals Inc. (ETON)
13.05
-0.46 (-3.40%)
At close: Mar 28, 2025, 3:59 PM
13.09
0.33%
After-hours: Mar 28, 2025, 04:27 PM EDT
-3.40% (1D)
| Bid | 12.5 |
| Market Cap | 349.97M |
| Revenue (ttm) | 40.03M |
| Net Income (ttm) | -3.92M |
| EPS (ttm) | -0.15 |
| PE Ratio (ttm) | -87 |
| Forward PE | 33.08 |
| Analyst | Strong Buy |
| Ask | 14.3 |
| Volume | 157,344 |
| Avg. Volume (20D) | 291,166 |
| Open | 13.52 |
| Previous Close | 13.51 |
| Day's Range | 12.83 - 13.64 |
| 52-Week Range | 3.03 - 18.41 |
| Beta | 1.37 |
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2018
Employees 31
Stock Exchange NASDAQ
Ticker Symbol ETON
Website https://www.etonpharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $26, which is an increase of 99.23% from the latest price.
Stock ForecastsNext Earnings Release
Eton Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+10.78%
Eton Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
4 months ago
+15.59%
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results. HC Wainwright & Co. reiterated a Buy rating on the stock.
